A bispecific antibody that binds human CD33 and CD3

By designing bispecific antibodies that bind human CD33 and CD3, using low-affinity CD3ε-ScFv and hydrophilic linking peptide technology, the non-specific toxicity of existing antibodies to normal cells is solved, and efficient orientation of leukemia cells is achieved Attack and safe healing effects.

CN118221826BActive Publication Date: 2024-11-15BEIJING LUZHU BIOTECH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410503481.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-04-25
Publication Date
2024-11-15
Estimated Expiration
2044-04-25

AI Technical Summary

Technical Problem

Existing bispecific antibodies have unnecessary effects on normal cells while attacking leukemia cells, resulting in non-specific toxicity and adverse reactions, and are not specific, making it difficult to provide highly targeted treatment.

Method used

A bispecific antibody that binds human CD33 and CD3 was designed, and a single-chain antibody that specifically recognizes CD33 and CD3 molecules was used to connect light and heavy chains using hydrophilic linking peptides, and a low-affinity CD3ε-ScFv was used as the linking. effector, reduces the impact on normal cells.

Benefits of technology

A highly directed attack on CD33-positive leukemia cells is achieved, reducing unnecessary impact on normal cells, reducing the risk of adverse reactions, and providing a safe and efficient treatment plan.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118221826B_ABST
    Figure CN118221826B_ABST
Patent Text Reader

Abstract

The present invention discloses a bispecific antibody combining human CD33 and CD3, and relates to the technical field of biomedicine. The bispecific antibody combining human CD33 and CD3 provided by the present invention utilizes human body's own T cells to kill CD33-positive cells, so as to achieve the purpose of treating myeloid leukemia. A new bispecific antibody molecule is designed on the basis of K193. The bispecific antibody of the molecular structure is a low-affinity CD3ε-ScFv single-chain antibody connected to the C-terminus of the light chain of the standard IgG1 molecular structure through a hydrophilic linker, so as to achieve the purpose of preferentially binding to the CD33 target, and simultaneously recognize CD33-positive myeloid leukemia cells and human body's own T cells. This specificity makes EK333F a highly directional therapeutic drug, which can guide T cells to attack leukemia cells while reducing unnecessary effects on normal cells.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine technology, and in particular to a bispecific antibody that binds human CD33 and CD3. Background Art

[0002] Acute myeloid leukemia (AML) is a genetically heterogeneous disease characterized by the clonal expansion of leukemic cells. Despite a better understanding of the biology of AML and the recent approval of new drugs for the treatment of AML, the 5-year overall survival rate with standard cytotoxic chemotherapy remains only 30%, and new therapies are urgently needed.

[0003] In recent years, T cell-based immunotherapy has attracted widespread attention as a promising immunotherapy for the treatment of various malignancies. AML cells are very sensitive to the cytotoxic effects of functional immune cells, and bispecific T cell engagers provide an effective means for the treatment of AML.

[0004] The CD33 molecule is a sialic acid-binding Ig-like lectin (Siglec) transmembrane glycoprotein with a molecular weight of 67KD and composed of 364 amino acids. It is specifically expressed on the surface of hematopoietic system cells, and its gene is located on human chromosome 19. It is a member of the immunoglobulin superfamily, with two immunoglobulin-like extracellular domains. It is also the fourth member of the sialic acid adhesion immunoglobulin-like lectin family, and together with sialic acid adhesion enzymes, CD22 and myelin-binding glycoproteins, it forms the adhesion family. Studies have shown that CD33 is a specific leukemia antigen for myeloid cells, which does not exist in hematopoietic stem cells but is expressed in hematopoietic cell subsets.

[0005] CD33 is expressed in 90% of acute myeloid leukemia (AML) cells. Although it is also expressed in myeloid hematopoietic progenitor cells, it is not expressed in normal hematopoietic stem cells. Studies have shown that targeted elimination of CD33-positive cells can restore their hematopoietic function through culture. Therefore, CD33 has become an ideal target for AML-specific immunotherapy, and the screening and use of CD33 monoclonal or bispecific antibodies have become a hot topic in medical research.

[0006] CD33 monoclonal antibodies produce anti-tumor effects through antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). In the early development of immunotherapy, studies using mouse anti-CD33 monoclonal antibodies such as M195, P67.7, and HIM3-4 found that they can activate complement-mediated cytotoxicity, induce cell endocytosis and macrophage chemotaxis, but the immunogenicity of mouse antibodies limits their reuse. With the development of antibody humanization technology and antibody engineering, humanized antibodies have been successfully constructed, overcoming the disadvantages of immunogenicity and achieving good clinical treatment effects.

[0007] In recent years, antibodies have been combined with toxins and drugs to form antibody-drug conjugates (ADCs), which enhance the cytotoxic effect of antibodies. Currently, a variety of anti-CD33 antibody drugs have been launched or are in clinical trials.

[0008] GO (Gemtuzumabozogamicin) is a conjugate of humanized anti-CD33 monoclonal antibody and potent anti-tumor antibiotic acetyl-calicheamicin, in which the monoclonal antibody contains about 98% of human amino acid sequence, and the rest is derived from murines. It binds to CD33 antigen on the surface of leukemia cells, releases calicheamicin after entering the cells, and has a significant killing effect on leukemia cells, thereby treating leukemia alone or in combination with other chemotherapy drugs.

[0009] In May 2000, GO was formally approved by the U.S. Food and Drug Administration (FDA) as a single agent for the treatment of CD33+ AML patients aged 60 years or older in first relapse. These patients were not eligible for standard chemotherapy, but the post-approval confirmatory clinical trial was terminated early and voluntarily withdrawn from the market due to lack of clinical benefit and increased adverse events. However, GO was reapproved in 2017 when further studies showed that adding GO to standard chemotherapy would be beneficial if fractionated doses of the drug were used.

[0010] CD3 is a marker present on the surface of all T lymphocytes. CD3 is also known as T3 or Leu-4. There are three subtypes, namely CD3δ, CD3ε and CD3γ. The molecular weight of CD3δ and CD3ε is 20kD, and the molecular weight of CD3γ is 26kD. It is expressed on the surface of T lymphocytes, thymocytes and NK cell membranes. It is expressed by 61% to 85% on normal peripheral blood lymphocytes and 60% to 85% on thymocytes. It belongs to the immunoglobulin superfamily. CD3 is a component of the T lymphocyte receptor (TCR) complex, forming a complex with α / β and γ / δ T lymphocyte receptors (TCR), and is the main membrane antigen that transmits TCR signals bound to peptides / MHC. TCR is essential for cell surface expression, antigen recognition and signal transduction.

[0011] CD3 is a specific molecule on the surface of T lymphocytes, through which T lymphocytes with cytotoxic effects can be recruited. Monoclonal antibodies to CD3 can induce or prevent T lymphocyte activation. In the presence of anti-CD28 antibodies or IL-2, anti-CD3 antibodies can induce apoptosis of T lymphocytes. CD3 is one of the best markers for mature T lymphocytes in peripheral blood. The determination of CD3+T lymphocytes is of great significance for the evaluation of immunodeficiency diseases (T lymphocyte deficiency), leukemia, and lymphoma (T lymphocyte type). Anti-CD3 monoclonal antibodies can be used for immunosuppressive therapy during organ transplantation or bone marrow transplantation, and can also be used for immunomodulatory therapy of severe autoimmune diseases to remove T lymphocytes. U.S. Patent No. 4,361,549 describes a mouse hybrid cell line for producing the monoclonal antibody OKT3 against antigens found in normal human T cells and skin T lymphoma cells. In addition, U.S. Patent No. 5,885,573 describes a humanized monoclonal antibody constructed by transferring mouse OKT3 into a human antibody framework in order to reduce its immunogenicity when used in humans and reduce the probability of human anti-mouse antibody (HAMA) reactions. OKT3 is the first mouse monoclonal drug approved by the U.S. FDA in 1986 for the treatment of acute rejection of organ transplantation, and is also the first monoclonal antibody drug approved for use by a government drug administration authority in the world. The main drawback of mouse OKT3 monoclonal antibody therapy is the T cell activation and HAMA reaction caused by the release of cytokines due to cross-linking between T cells and FcγR-bearing cells. After more than 10 years of use on the market, OKT3 was eventually replaced by humanized antibodies and new small molecule immunosuppressants. On the other hand, OKT3 or other anti-CD3 antibodies can be used as immunopotentiators to stimulate T cell activation and proliferation. Anti-CD3 monoclonal antibodies, combined with anti-CD28 antibodies or interleukin-2 in in vitro cell culture can induce T cell proliferation. OKT3 is further used alone or as a component of a bispecific antibody to target cytotoxic T cells to tumor cells and virus-infected cells. So far, the use of antibodies as T cell recruitment agents has been hindered by several discoveries. First, natural or modified antibodies with high affinity for T cells often do not activate the T cells to which they bind; second, natural or modified antibodies with low affinity for T cells are usually ineffective or ineffective in eliciting T cell-mediated cell lysis, so it is very important to choose an anti-CD3 monoclonal antibody with appropriate affinity.

[0012] Several companies at home and abroad have been researching and developing CD33-CD3ε bispecific antibodies. Currently, four bispecific antibodies targeting CD33 are being evaluated in phase 1 clinical trials.

[0013] AMG330 (developed by Amgen) is a short-acting BiTE molecule that requires continuous intravenous (IV) infusion in a cycle of 2 to 4 weeks. Preclinical studies have shown that the anti-CD33x anti-CD3 structure of the BiTE model is cytotoxic even at low CD33 antigen density on target cells, making it a candidate for targeting a wide range of CD33+ leukemias (including AML).

[0014] As of November 2022, 96 people have been enrolled in the clinical study, and clinical trial data showed that 55 patients with relapsed or refractory (r / r) AML have been included in a Phase 1 trial (NCT02520427) to evaluate the safety of AMG330 and determine its maximum tolerated dose. Eight of the 42 evaluable patients (19%) responded to AMG330, including three complete remissions (CR), four complete remissions with incomplete blood recovery (CRi), and one leukemia-free state (MLFS). The results of the Phase 1 trial showed that AMG330 doses of up to 720 μg / day can provide early evidence of acceptable safety, drug tolerability, and anti-leukemia activity, and support further dose escalation studies to provide a trial basis.

[0015] AMG673 (R&D institution: Amgen) is a half-life extended BiTE structure that combines the binding specificity of CD33 and CD3, fused to the N-terminus of a single IgGFc region. The expected terminal half-life of AMG673 in humans is expected to increase to 21 days. AMG673 is administered in a 14-day cycle with two short intravenous infusions on days 1 and 5. As of March 2022, 30 patients were enrolled in the Phase 1 trial of AMG673 (NCT03224819), and 11 of the 27 evaluable patients (41%) had blast reduction, including 5 patients with a blast reduction rate of more than 50%. One of the 27 (4%) evaluable patients achieved CR. The results of the Phase 1 trial showed that preliminary data with AMG673 doses up to 72μg provided early evidence that the molecule has acceptable safety, drug tolerability, and anti-leukemia activity. AMV564 (development institution: Amphivena Therapeutics, Inc) is a tetravalent anti-CD33 x anti-CD3 tandem diabody (TandAb) structure, which is continuously intravenously infused at 14-day intervals. Because AMV564 is tetravalent, with two CD3 binding sites and two CD33 binding sites, the drug has increased affinity for both targets. AMV564 has a higher molecular weight than monovalent bispecific antibodies and therefore has a longer half-life. Preclinical in vitro and in vivo studies have demonstrated that AMV564 can induce potent cytotoxicity in CD33+ AML cell lines in a dose-dependent manner.

[0016] AMV564 is currently being evaluated in a Phase 1 trial (NCT03144245), and as of May 2021, 36 patients have been enrolled in this study. Three of the 35 evaluable patients (9%) had an objective response, including one CR, one CRi, and one partial remission (PR). Seventeen of the 35 evaluable patients (49%) had blast reductions.

[0017] JNJ-67561244 (developed by Janssen) is a fully human IgG4-PAA bispecific antibody that binds to the C2 domain of CD33 and CD3 to induce T cell recruitment and tumor cell cytotoxicity. JNJ-67571244 specifically binds to CD33-expressing cells and mediates specific in vitro T cell-dependent cytotoxicity against AML cell lines and primary patient samples.

[0018] JNJ-67571244 was well tolerated in cynomolgus monkeys up to 30 mg / kg. JNJ-67571244 mediated potent cytotoxicity in cell lines and primary samples, regardless of their SNP genotype status, suggesting potential therapeutic benefit compared to other V-binding antibodies. JNJ-67571244 is currently in a Phase 1 clinical trial (NCT03915379) in patients with relapsed / refractory AML and high-risk myelodysplastic syndrome. No clinical data have been reported for JNJ-67561244.

[0019] However, traditional bispecific antibodies have low specificity. While attacking leukemia cells, they may also have unnecessary effects on normal cells. There is a certain probability that nonspecific immune responses will be triggered during the treatment process. Due to the lack of high specificity, these antibodies may attack normal cells, not just leukemia cells, which leads to the so-called "nonspecific toxicity", that is, normal tissues are damaged, resulting in poor treatment effects, and higher doses are required to achieve therapeutic effects, thereby increasing patient discomfort and risks. At the same time, traditional bispecific antibodies have defects in the selection of specific affinities or linked effectors, which may lead to over-activation of T cells or other adverse reactions. If the affinity of the bispecific antibodies selected is too high or the linked effectors are too strong, they may lead to over-activation of T cells, which may trigger strong immune responses, including cytokine release syndrome, and reduce the safety of treatment. Therefore, there is an urgent need for a bispecific antibody that binds to human CD33 and CD3 while providing highly targeted treatment and binding in a low-affinity manner. Summary of the invention

[0020] 1. Technical issues to be solved

[0021] In view of the deficiencies of the prior art, the present invention provides a bispecific antibody that binds human CD33 and CD3, thereby solving the problems in the prior art that the bispecific antibodies have low specificity, may have unnecessary effects on normal cells, and have defects in the selection of specific affinity or connection effectors.

[0022] (II) Technical solution

[0023] To achieve the above objectives, the present invention is implemented by the following technical solutions. The present invention provides a bispecific antibody that binds human CD33 and CD3, comprising:

[0024] 1) IgG antibody that specifically binds to the cell membrane antigen CD33;

[0025] 2) Single-chain antibody that binds to CD3 molecule, an antigen on the surface of T cells;

[0026] The single-chain antibody that recognizes the CD3 molecule is connected to the C-terminus of the CD33 antibody light chain via a hydrophilic connecting peptide;

[0027] The bispecific antibody structure is:

[0028]

[0029] and,

[0030] Linker1: GSTSGSGKPGSGEGSTKGGS;

[0031] Linker2: GGGGSGGGGSGGGGS;

[0032] Wherein, the VH-CH1-Hinge Region-CH2-CH3 amino acid sequence is sequence 5;

[0033] The VL-Cκ-Linker1-VH(CD3)-Linker2-VL(CD3) amino acid sequence is shown in Sequence 6.

[0034] The present invention is further configured as follows: the single-chain antibody structure for recognizing CD3 molecules is in the form of ScFv, which is directed against human CD3ε and can be derived from the variable region gene sequences of various currently known monoclonal antibodies, including but not limited to the CD3-specific antibodies of OKT3, X35-3, WT31, WT32, SPv-T3b, TR-66, 11D8, 12F6, M-T301, SMC2 and F101.01;

[0035] The present invention is further configured as follows: the CD33 recognition heavy chain variable region sequence and the anti-human CD33 monoclonal antibody light chain sequence, wherein the monoclonal antibody light chain contains the kappa chain Cκ region, can be derived from the variable region gene sequences of various currently known monoclonal antibodies, or the anti-CD33 monoclonal antibody heavy chain and light chain variable region sequences constructed by the company;

[0036] The present invention is further configured as follows: the nucleotide sequence and amino acid sequence contained in the heavy chain containing the guide peptide are as shown in Sequence 1 and Sequence 2;

[0037] The nucleotide sequence and amino acid sequence of the light chain containing the guide peptide are shown in SEQ ID NO: 3 and SEQ ID NO: 4;

[0038] The amino acid sequence contained in the heavy chain without the guide peptide is shown in SEQ ID NO: 5;

[0039] The amino acids contained in the light chain without the guide peptide are shown in Sequence 6;

[0040] The present invention also provides a method for preparing a bispecific antibody, which is prepared by gene recombination technology, using different types of mammalian cell expression vectors, and expressing in CHO cells. The CHO cells are cultured in a chemically defined medium, and no hormones and various animal-derived proteins or their hydrolysates are added during the culture process.

[0041] The present invention is further configured as follows: a single plasmid vector containing a bispecific antibody gene is linearized by digestion with a single endonuclease;

[0042] After transfection of CHO cells, positive clones were obtained, which were then cultured in a bioreactor, and the products were secreted into the culture supernatant;

[0043] Purification is performed using ion exchange chromatography media or affinity chromatography combined with ion exchange chromatography to obtain a bispecific antibody that can specifically bind to human CD33 and CD3;

[0044] The present invention is further configured as follows: the bispecific antibody is used as a therapeutic drug for treating relapsed and refractory myeloid leukemia, and is a T cell-dependent immunotherapy drug for killing myeloid leukemia cells;

[0045] The present invention also provides a pharmaceutical composition of any of the above-mentioned bispecific antibodies;

[0046] The present invention is further configured as follows: the pharmaceutical composition can be prepared into a liquid preparation or a freeze-dried preparation, can be administered continuously using a continuous infusion pump, can be administered regularly using a pulse infusion pump, is recommended to be administered intravenously, and can also be administered subcutaneously;

[0047] The present invention is further configured as follows: the liquid preparation, freeze-dried preparation, and liquid preparation stabilizer formula comprise:

[0048] Acetic acid: 0.2~0.4g / L

[0049] L-methionine: 1.0~20g / L

[0050] L-histidine: 1.0~2.0g / L

[0051] Tween-20: 0.2~1.0g / L

[0052] Sucrose: 50-150g / L.

[0053] (III) Beneficial effects

[0054] The present invention provides a bispecific antibody that binds human CD33 and CD3, and has the following beneficial effects:

[0055] The EK333F of the present invention is a bispecific antibody targeting CD33 and CD3, through which the human body's own T cells can be used to kill CD33-positive cells to achieve the purpose of treating myeloid leukemia.

[0056] The EK333F bispecific antibody of the present invention is a bispecific antibody targeting CD33 and CD3. After using EK333F for 7-10 days of low-dose slow induction treatment, an appropriate dose of EK333F antibody is used for treatment, providing an optional treatment method for patients with relapsed / refractory myeloid leukemia.

[0057] The molecular structure of EK333F is fundamentally different from other bispecific antibodies that have entered the clinical research stage, and has the advantage of better targeting. At the same time, the low-affinity CD3ε-ScFv of the present invention is used as a weak binding molecule to connect effector-T cells. Even if each EK333F molecule contains two CD3 binding sites, it cannot activate T cells like OKT3.

[0058] When researching and developing EK333F, the present invention also initially drew on the molecular structure of our company's K193 (patent number 201711131955.0). However, K193 targets CD19. Such B cells express a high amount of B7 and are easy to activate T cells, while CD33-positive myeloid leukemia cells express a low amount of B7. Early NSG mouse animal experiments showed that the therapeutic effect was poor. Therefore, we designed a new bispecific antibody molecule based on K193, with a structure such as Figure 1As shown. The bispecific antibody of this molecular structure is a low-affinity CD3ε-ScFv single-chain antibody connected to the C-terminus of the light chain of the standard IgG1 molecular structure through a hydrophilic linker, thereby achieving the purpose of preferential binding to the CD33 target.

[0059] In summary, the EK333F provided in the present application is a bispecific antibody targeting CD33 and CD3, which simultaneously recognizes CD33-positive myeloid leukemia cells and the body's own T cells. This specificity makes EK333F a highly targeted therapeutic drug that can direct T cells to attack leukemia cells while reducing unnecessary effects on normal cells.

[0060] At the same time, the treatment method proposed in this application includes 7-10 days of low-dose slow induction treatment, followed by treatment with an appropriate dose of EK333F antibody. This treatment method combines the use of bispecific antibodies and specific treatment time and dosage, providing a new treatment option for patients with relapsed / refractory myeloid leukemia.

[0061] In terms of molecular structure, the molecular structure of EK333F uses low-affinity CD3ε-ScFv as a connecting effector, and its affinity for binding to T cells is weaker, which helps prevent over-activation of T cells, thereby reducing adverse reactions, while ensuring preferential binding to the CD33 target.

[0062] The invention solves the problems existing in the prior art that the bispecific antibodies have low specificity, may have unnecessary effects on normal cells, and have defects in the selection of specific affinity or connection effectors. BRIEF DESCRIPTION OF THE DRAWINGS

[0063] Figure 1 It is a structural diagram of EK333F of the present invention;

[0064] Figure 2 This is the linearized agarose electrophoresis pattern of plasmid DGV-EK333F-Line;

[0065] Figure 3 This is the affinity chromatography purification profile of EK333F bispecific antibody;

[0066] Figure 4 This is the HPLC-SEC chromatogram of EK333F bispecific antibody after affinity chromatography purification;

[0067] Figure 5 This is the anion exchange chromatography purification profile of EK333F bispecific antibody;

[0068] Figure 6 This is the HPLC-SEC chromatogram of EK333F bispecific antibody after ion exchange chromatography purification;

[0069] Figure 7 This is the HPLC-SEC chromatogram of EK333F bispecific antibody after ultrafiltration;

[0070] Figure 8 is the binding activity of EK333F bispecific antibody to CD33-positive cells;

[0071] Fig. 9 is the binding activity of EK333F bispecific antibody to T cells;

[0072] Fig.10 The ability of the EK333F bispecific antibody to efficiently activate T cells in the presence of CD33-positive cells;

[0073] Fig.11 The relationship between the change of luminescence signal intensity and EK333F dose in animal live imaging;

[0074] Fig.12 The in vivo imaging photos of animals show the therapeutic effect of EK333F. DETAILED DESCRIPTION

[0075] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0076] Example

[0077] See also Figure 1-Figure 12 The present invention provides a bispecific antibody that binds human CD33 and CD3, namely EK333F, which can be used to kill CD33-positive cells by using the body's own T cells to achieve the purpose of treating myeloid leukemia.

[0078] The EK333F bispecific antibody of the present invention is a bispecific antibody targeting CD33 and CD3. After using EK333F for 7-10 days of low-dose slow induction treatment, an appropriate dose of EK333F antibody is used for treatment, providing an optional treatment method for patients with relapsed / refractory myeloid leukemia.

[0079] The molecular structure of EK333F is fundamentally different from other bispecific antibodies that have entered the clinical research stage, and has the advantage of better targeting. At the same time, the low-affinity CD3ε-ScFv of the present invention is used as a weak binding molecule to connect effector-T cells. Even if each EK333F molecule contains two CD3 binding sites, it cannot activate T cells like OKT3.

[0080] When researching and developing EK333F, the present invention also initially drew on the molecular structure of our company's K193 (patent number 201711131955.0). However, K193 targets CD19. Such B cells express a high amount of B7 and are easy to activate T cells, while CD33-positive myeloid leukemia cells express a low amount of B7. Early NSG mouse animal experiments showed that the therapeutic effect was poor. Therefore, we designed a new bispecific antibody molecule based on K193, with a structure such as Figure 1 shown.

[0081] The bispecific antibody of this molecular structure is a low-affinity CD3ε-ScFv single-chain antibody connected to the C-terminus of the light chain of the standard IgG1 molecular structure through a hydrophilic linker, thereby achieving the purpose of preferential binding to the CD33 target.

[0082] The EK333F bispecific antibody was expressed using a CHO cell expression system. After optimizing the chemically defined culture medium, the unit yield of the antibody has reached more than 1.5 grams per liter.

[0083] The present invention provides a bispecific antibody that binds to human CD33 and CD3. The bispecific antibody is composed of CD33 molecules on the surface of human myeloid leukocytes and human CD3 molecules that specifically recognize human CD33 molecules. The anti-human CD33 molecule heavy chain variable region gene is connected to human IgG CH1 and Fc region genes, wherein the gene containing the anti-human CD33 monoclonal antibody light chain (containing the kappa chain Cκ region) is connected to the anti-human CD3 single-chain antibody heavy chain gene through a hydrophilic connecting peptide Linker1, and then connected to the anti-human CD3 single-chain antibody light chain gene through a hydrophilic connecting peptide Linker2;

[0084] The bispecific antibody structure is as follows:

[0085]

[0086] Linker1:GSGSSGKPGSGEGSTKGGS;

[0087] Linker2: GGGGSGGGGSGGGGS;

[0088] The amino acid sequence of VH-CH1-Hinge Region-CH2-CH3 is shown in SEQ ID NO: 5;

[0089] The amino acid sequence of VL-Cκ-linker1-VH(CD3)-linker2-VL(CD3) is shown in SEQ ID NO: 6;

[0090] The nucleotide sequence contained in the heavy chain containing the gene sequence encoding the guide peptide is shown in SEQ ID NO: 1, relative to the position of nucleotides 1 to 70 of the structural formula;

[0091] The positions of the CD33 heavy chain variable region sequence, human IgG1 CH1, and Fc sequences relative to nucleotides 71-1408;

[0092] The amino acid sequence contained in the heavy chain containing the leader peptide sequence is shown in SEQ ID NO: 2;

[0093] The guide peptide sequence is relative to amino acids 1 to 19. Amino acids 20 to 135 are VH (CD33), amino acids 136 to 233 are human IgG1 CH1, and amino acids 237 to 465 are IgG1 Fc;

[0094] The nucleotide sequence contained in the light chain containing the gene sequence encoding the leader peptide is shown in SEQ ID NO: 3, relative to the position of nucleotides 1-73;

[0095] The position of the CD33 light chain variable region relative to nucleotides 74-406;

[0096] human IgG1 Cκ relative to nucleotides 407-727;

[0097] the position of the connecting peptide relative to nucleotides 728–787 and 1163–1207;

[0098] VH (CD3) corresponds to positions of nucleotides 788-1162; VL (CD3) corresponds to positions 1208-1534.

[0099] The amino acid sequence of the light chain containing the guide peptide sequence is shown in SEQ ID NO. 4, and the guide peptide sequence is relative to the 1st to 20th amino acids;

[0100] The 21st to 238th amino acids are VH (CD33) + IgG1 Cκ, the 239th to 258th amino acids are the connecting peptide GSTSGSGKPGSGEGSTKGGS, the 384th to 398th amino acids are the connecting peptide (G4S) 3, the 259th to 383rd amino acids are VH (CD3), and the 399th to 507th amino acids are VL (CD3).

[0101] The sequence without the amino acids contained in the heavy chain of the guide peptide is shown in SEQ ID NO:5.

[0102] The amino acid sequence of the light chain without the guide peptide is shown in SEQ ID NO:6.

[0103] The Fab structural fragment that specifically recognizes the human CD33 antigen can be derived from the sequences of the light chain and heavy chain variable regions of various well-known mouse anti-human CD33 monoclonal antibodies, or other known human CD33 monoclonal antibody variable region sequences, or the sequences of the heavy chain and light chain variable regions of the anti-CD33 monoclonal antibodies constructed by the company.

[0104] The single-chain antibody structure that recognizes the CD3 molecule is in the form of ScFv, which is targeted at human CD3ε and can be derived from the variable region gene sequences of various currently known monoclonal antibodies, including but not limited to the CD3-specific antibodies of OKT3, X35-3, WT31, WT32, SPv-T3b, TR-66, 11D8, 12F6, M-T301, SMC2 and F101.01.

[0105] The present invention further provides a method for preparing the bispecific antibody of the present invention, wherein the bispecific antibody is prepared by using a gene

[0106] The recombinant technology can be used for expression in various forms of mammalian cells, preferably CHO cells. The CHO cells are cultured in a chemically defined medium, and no hormones or proteins or their hydrolysates derived from toxic substances are added during the culture process.

[0107] The preparation method of the present invention comprises linearizing a single plasmid vector containing a bispecific antibody gene by digesting it with a single endonuclease, transfecting CHO cells to obtain a positive clone, culturing in a bioreactor, secreting the product into the culture supernatant, and purifying it by ion exchange chromatography medium or affinity chromatography combined with ion exchange chromatography to obtain a bispecific antibody that can specifically bind to human CD33 and CD3.

[0108] The bispecific antibody provided by the present invention is a therapeutic drug for treating relapsed / refractory myeloid leukemia, and is a T cell-dependent immunotherapy drug for killing myeloid leukemia cells.

[0109] The present invention further provides a pharmaceutical composition containing the bispecific antibody of the present invention. The pharmaceutical composition can be prepared as a liquid preparation or a lyophilized preparation, and can be administered continuously using a continuous infusion pump or periodically using a pulse infusion pump. Intravenous administration is recommended, and subcutaneous injection can also be used.

[0110] The bifunctional antibody constructed by the technology of the present invention successfully achieved high-level stable expression in CHO cells, and obtained high-purity bifunctional antibodies through purification methods such as liquid chromatography, and a variety of liquid preparations were developed for the antibodies; using the liquid preparation formula provided by the present invention, the bispecific antibody has stable quality within a concentration range of 0.1-30 mg / ml under the condition of storage at 2-8° C. in the dark.

[0111] The present invention provides a tumor-targeting molecule antibody with high affinity and a CD3 antibody with relatively weak binding ability. The two are connected by a hydrophilic peptide chain of appropriate length, which provides sufficient free extension space for the antibody-specific binding part. The molecular structure has good thermal stability and produces less aggregates, which maximizes the stability and excellent binding ability of the antibody molecule. The excellent liquid preparation formula and stable molecular structure provide guarantees for convenient clinical safe drug administration.

[0112] The molecular structures of four CD33-targeting bispecific antibodies in the prior art are compared with those of the present invention, as shown in Table 1:

[0113] Table 1: Comparison of the molecular structure of the present invention with four existing CD33 bispecific antibodies

[0114]

[0115] Example 1

[0116] Construction of plasmid expression vector

[0117] Construction of plasmids SGV-K33H (pKC2+CD33VH+hIgG1 CH1+Hinge Region+hIgG1 Fc) and SGV-EK333FL (pKC1+CD33Vk+hIgG1 Cκ+Anti-Human-CD3-ScFv).

[0118] The plasmid SGV-K3331H (containing Anti-Humanized CD33 VH sequence), pKC2 (vector sequence) and IgGCT-1 (hIgG1 CH1+Hinge Region+hIgG1 Fc sequence) were treated with corresponding restriction endonucleases to obtain the digestion products CD33VH-HindIII / SalI, IgGCT-SalI / EcoRI and pKC2-HindIII / EcoRI. The three digestion products were ligated, transformed into DH5α and screened to obtain the positive clone SGV-K33H (pKC2+CD33VH+hIgG1 CH1+HingeRegion+hIgG1 Fc).

[0119] The fragment CD33VL+hIgG1 was amplified from the plasmid SGV-K3331L containing the humanized anti-CD33 mAb light chain using primers VSNF1 and CKL3R and L3M3F and M3VR, respectively. Cκ and introduced KOZAK sequence and light chain signal peptide sequence, and amplified the fragment Anti-Human-CD3-ScFv (containing Linker2 ((G4S)3) sequence and introduced Linker1 (GSTSGSGKPGSGEGSTKGGS) from the plasmid SGV-K3331H containing the heavy chain of humanized anti-CD33 monoclonal antibody; the plasmid pKC1 (vector sequence) was treated with restriction endonucleases to obtain the enzyme digestion product pKC1-HindIII / EcoRI; the two fragments were bridged and then homologously recombined with pKC1-HindIII / EcoRI to obtain the plasmid SGV-EK333FL. Different clones were sent to a sequencing company (Beijing Liuhe BGI Gene Technology Co., Ltd.) for sequencing and completely correct clones were selected for the next step of the experiment.

[0120] Table 2: Primer sequences

[0121]

[0122] DGV-EK333F Build:

[0123] SGV-K33H and SGV-EK333FL were treated with restriction endonucleases NotI and PvuI to obtain the digestion products K33H-N / P and EK333FL-N / P. The two digestion products were connected by ligase, transformed into DH5α and screened to obtain the positive clone DGV-EK333F. The plasmid DGV-EK333F was extracted in large quantities and linearized with restriction endonuclease PvuI and purified by phenol extraction to obtain the linearized plasmid DGV-EK333F-Line. The agarose electrophoresis photo of the linearized plasmid is attached. Figure 3 .

[0124] Example 2

[0125] Establishment and screening of stable clones

[0126] In a sterile laminar flow bench, the perforation voltage of the gene pulse generator Xcell (Bio-Rad) was set to 300 V, 900 μF, and exponential pulse. A disposable electroporation cup with a gap of 4 mm was taken out, 40 μg of linearized plasmid DNA (100 μl) and 0.7 ml of CHO K1 cell (GSKO) suspension were added, and the resistance of the electroporator was set to infinity. The linearized plasmid 193HVkP- was transfected into CHOK1 cells by electrofection. The cells in the electroporation cup were transferred to a triangular culture flask, CD CHO culture medium was added, and the cells were cultured on a shaker at 36-37°C and 5% CO2 at 135 rpm for 24 hours. The cells were collected by low-speed centrifugation and replaced with CD CHO culture medium containing 50 μM MSX. CHO culture medium (without glutamine), monoclonal cell lines were obtained by limiting dilution method, and then clones with higher expression levels were screened out by ELISA method (mouse anti-human κ chain monoclonal antibody + expression product K33 + goat anti-human IgG-HRP) and subcultured, and finally 5 clones were obtained. According to the antibody expression level in the culture supernatant and the cell growth condition, the one with the highest expression level was selected for subcloning; monoclonal cell lines were obtained by limiting dilution method again, and then clones with higher expression levels were screened out by the same ELISA method and subcultured, and finally 5 clones were obtained, and the clone with the highest expression level (named EK333F) was selected for expanded culture.

[0127] Example 3

[0128] EK333F fermentation and purification

[0129] The obtained EK333F clone was inoculated into a 2L or 3L Erlenmeyer flask containing 500ml CD CHO culture medium, and cultured on a shaker at 36-37°C and 5% CO2 at 130-140 rpm. After 3-6 days of culture, the culture was transferred to a bioreactor.

[0130] Reactor culture conditions: initial inoculation density of the reactor: 500,000 to 2,000,000, culture temperature 32 to 37°C, pH 6.5 to 7.5, stirring speed 50 to 120 rpm, dissolved oxygen 50% ± 20%, intermittent feeding during culture (feeding such as sugar, culture medium or alkali solution, etc.), culture time 12 to 18 days, harvest when the viable cell density drops to between 60% and 70%.

[0131] The harvested culture fluid was centrifuged at 10000r / min for 30 minutes to remove cells and cell debris, and the cell culture supernatant was collected and then purified by affinity chromatography gel (such as Protein At Bead LX). The affinity chromatography was subjected to pre-dissociation and dissociation processes. The concentration of the dissociation solution was 0.1mol / L citric acid-sodium citrate (pH2.0-4.5). The protein purity after affinity chromatography reached more than 96%. The affinity chromatography dissociation spectrum is detailed in the attached Figure 3 , purity spectrum see attached Figure 4 ; Then through anion exchange chromatography gel such as DEAE Sepharose Fast Flow (see attached Figure 5 ) After purification, the purity can reach more than 99%, the purity spectrum is attached Figure 6 The purified liquid is concentrated by ultrafiltration and fully replaced with a stabilizer solution to form a stock solution.

[0132] Example 4

[0133] EK333F stock stabilizer formula:

[0134] Acetic acid: 0.2~0.4g / L

[0135] L-methionine: 1.0~20g / L

[0136] L-histidine: 1.0~2.0g / L

[0137] Tween-20: 0.2~1.0g / L

[0138] Sucrose: 50-150 g / L

[0139] The purified liquid is the EK333F bispecific antibody. The bispecific antibody was analyzed for purity on a Shimadzu LC-20AT HPLC TSK 3000SW xl (7.8*300mm) column using 40mM PBS (containing 0.5M Na2SO4, pH 6.5) as the mobile phase. The test results showed that the purity was not less than 95%, the polymer content was less than 5%, and no visible impurity peaks were found. The results are detailed in the attached Figure 7 .

[0140] Example 5

[0141] Binding activity test of CD33-CD3 bispecific antibody to CD33 positive cells

[0142] U937 cells express CD33 antigen on their surface, and antibodies that recognize CD33 can specifically bind to CD33 antigen on the cell surface. Flow cytometry was used to detect the specific binding of CD33-CD3 bispecific antibody sample EK333F to CD33 site of U937 cells. This experiment selected K333 antibody (Fab-ScFv) solution and CD33 antibody K33 solution as control samples, among which EK333F molecule contains CD33 and CD3 dual binding sites, K333 only contains CD33 and CD3 single binding sites, and K33 is a human CD33 monoclonal antibody. Flow cytometry (NovoCyte 3130, Aisen Biological (Hangzhou) Co., Ltd.) was used to detect the specific binding activity of EK333F antibody to CD33 site of U937 cells.

[0143] Dilute the EK333F antibody with 0.02 mol / L PBS (pH 7.4, containing 1% BSA) to an initial protein concentration of 3 mg / ml. Take a 96-well U-shaped plate and add 50 μl of 0.02 mol / L PBS (pH 7.4, containing 1% BSA) to wells 1 to 3 in row B as blank control wells. Add 50μl of 0.02mol / L PBS (pH 7.4, containing 1% BSA) to wells 1 to 11 in rows C, D, and E, and wells 1 to 3 in rows F to H, then add 75μl of EK333F antibody diluted to 3mg / ml to wells C12, D12, and E12, pipette 25μl of antibody solution in wells C12, D12, and E12, dilute to wells C1, D1, and E1 in a 3-fold gradient from right to left, mix well, move to wells F3, G3, and H3, continue gradient dilution to wells F1, G1, and H1, mix well, aspirate 25μl, discard, and keep the volume of each well at 50μl. The dilution range is 3mg / ml to 0.627ng / ml, with a total of 15 dilutions. Prepare a cell suspension with a cell density of 5.0×106 cells / ml, add 100 μl of U937 cell suspension to the above sample wells, mix well, react at room temperature for 60 minutes, centrifuge and carefully aspirate and discard the supernatant.

[0144] Except for the blank control B2 well, 50 μl of 0.02 mol / L PBS (pH 7.4, containing 1% BSA) was added, and 50 μl of mouse anti-human IgG-κ chain monoclonal antibody diluted to 2 μg / ml was added to the other wells, mixed and allowed to react at room temperature for 60 minutes, and then centrifuged and carefully aspirated the supernatant and discarded. 50 μl of 0.02 mol / L PBS (pH 7.4, containing 1% BSA) was added to the blank control B1 well, and 50 μl of diluted FITC-labeled goat anti-mouse IgG (1:500) was added to the sample well, mixed and allowed to react at room temperature in the dark for 30 minutes, and then centrifuged and carefully aspirated the supernatant and discarded. 170 μl of 0.02 mol / L PBS (pH 7.4) was added to each well, and the cells in the well were resuspended and mixed. The flow cytometer gate loading volume was set to 10,000, the sample flow rate was set to high speed, and the cell fluorescence value was measured and the fluorescence value was counted (minus the blank control fluorescence value).

[0145] The EC50 value of EK333F antibody was calculated by GraphPad Prism5.0 software to be 2.406×10-9mol / L, while the EC50 values ​​of the control samples K333 bifunctional antibody and CD33 antibody K33 were 1.074×10-8mol / L and 8.220E-10mol / L, respectively. The binding activity of EK333F to U937 cells was better than that of K333 protein. The binding activity of K33 monoclonal antibody to CD33 was better than that of EK333F (see Figure 8 ).

[0146] Example 6

[0147] Flow cytometry determination of the binding activity of EK333F antibody to T cells

[0148] To test the ability of the EK333F bispecific antibody to bind to the T cell surface molecule CD3, we performed flow cytometry analysis (FACS) on the obtained bispecific antibody.

[0149] Jurkat cells are T lymphocytes with CD3 antigens on their cell surface, which can specifically bind to the CD3 antigen on the cell surface. Flow cytometry was used to detect the specific binding of the bispecific antibody sample EK333F to the CD3 site of Jurkat cells. This experiment selected K333 antibody solution and OKT3 antibody solution as control samples, among which EK333F is a tetramer, K333 is a dimer, the molecular weight of EK333F is 2.7 times that of K333, and OKT3 is a CD3 site monoclonal antibody. Flow cytometry (NoveCyte 3130, Aisen Biological (Hangzhou) Co., Ltd.) was used to detect the specific binding activity of EK333F antibody to the CD3 site of Jurkat cells.

[0150] Dilute EK333F antibody with 0.02mol / L PBS (pH 7.4, containing 1% BSA) to an initial protein concentration of 300μg / ml. Take a 96-well U-shaped plate and add 50μl of 0.02mol / L PBS (pH 7.4, containing 1% BSA) to wells 1 to 3 in row B as blank control wells. Add 50μl of 0.02mol / L PBS (pH 7.4, containing 1% BSA) to wells 1 to 11 in rows C, D, and E, respectively. Then add 75μl of antibody solution diluted to 300μg / ml to wells C12, D12, and E12. Use a pipette to draw 25μl of antibody solution in wells C12, D12, and E12, and dilute it to wells C1, D1, and E1 in a 3-fold gradient from right to left. After mixing, aspirate 25μl and discard it, keeping the volume of each well at 50μl. The dilution range is 300μg / ml~1.694ng / ml, with a total of 12 dilutions. Prepare a cell suspension with a cell density of 2.0×106cells / ml, add 100μl of Jurkat cell suspension to the above sample wells, mix well, place at 37℃ for 60 minutes, centrifuge and carefully aspirate and discard the supernatant.

[0151] Except for the blank control B2 well, 50 μl of 0.02 mol / L PBS (pH 7.4, containing 1% BSA) was added. 50 μl of mouse anti-human IgG-κ chain monoclonal antibody diluted to 2 μg / ml was added to the remaining wells, mixed and placed at room temperature for 60 minutes, and then centrifuged and carefully aspirated the supernatant and discarded. 50 μl of 0.02 mol / L PBS (pH 7.4, containing 1% BSA) was added to the blank control B1 well, and 50 μl of diluted FITC-labeled goat anti-mouse IgG (1:100) was added to the sample well, mixed and placed at 37°C in the dark for 60 minutes, and then centrifuged and carefully aspirated the supernatant and discarded. 170 μl of 0.02 mol / L PBS (pH 7.4) was added to each well, and the cells in the well were resuspended and mixed. The sample loading volume in the flow cytometer gate was set to 10,000, the sample flow rate was set to high speed, and the cell fluorescence value was measured and the fluorescence value was counted (minus the blank control fluorescence value). The EC50 value of EK333F antibody was calculated using GraphPad Prism5.0 software.

[0152] The EC50 values ​​were 8.585E-09, 2.216E-09, and 4.379E-10 (mol / L), respectively. The binding activity of EK333F bispecific antibody to Jurkat cells was determined ( Fig. 9 ).

[0153] Example 7

[0154] Flow cytometry measurement of the activity of EK333F bispecific antibody in activating T cells (CD69)

[0155] EK333F antibody was diluted to a series of concentrations (6.4pg / ml~500μg / ml) with 10% FCS1640 culture medium and added to 48-well cell culture plates. Jurkat cells were adjusted to a density of 3×106 / ml with 10% FCS1640 culture medium, and U937 cells were adjusted to a cell density of 3×105 / ml. Jurkat cells and U937 cells were mixed in equal volumes (the ratio of effector to target was 10:1), and 200μl / well of the mixed cell suspension was added to a 48-well cell culture plate; at the same time, a control group without B cells was set up, that is, 200μl / well of the serially diluted antibody solution and the Jurkat cell solution with a density of 3×106 / ml were added to a 48-well cell culture plate. Then, the cells were cultured in a 10% CO2, 37°C incubator for 18 hours, and 150 μl of the co-culture was taken out, the supernatant was removed by centrifugation, and the sample was mixed with 6 μl (1:1) of Anti-Human CD69PE (clone: ​​FN50, LOT: 2264967, eBioscience) for 120 minutes in the dark, and then the supernatant was discarded by centrifugation. The cells were resuspended in 0.02 mol / L PBS (pH 7.4), and the average fluorescence intensity of CD69 expressed by the cells was determined by flow cytometry. The results were fitted by GraphPad Prism 5.0 software, and the measured concentrations were used as the horizontal axis and the average fluorescence intensity of the cells was used as the vertical axis to analyze the quantitative response relationship of the expression of CD69 molecules on the surface of Jurkat cells after stimulation with various concentrations of EK333F, and the EC50 value was fitted. The EC50 in the presence of U937 cells was 2.927E-11 (mol / L), while the EC50 in the absence of U937 cells was only 9.742E-09 (mol / L). Based on the above data, it can be seen that the ability of EK333F to activate T cells is 333 times higher in the presence of U937 cells.

[0156] In the absence of CD33-positive cells, the fluorescence value of CD69 was low. Even when EK333F reached 500 ng / ml, the fluorescence value was about 2.7 times the background value. Therefore, EK333F alone could not stimulate T cells to activate well.

[0157] The results of this experiment show that after being activated by EK333F, a large number of CD69 molecules are expressed on the surface of Jurkat cells. This is the co-stimulatory effect of EK333F antibody under the co-stimulation of U937 cells. These two conditions are indispensable, and efficient activation of T cells cannot be achieved under a single condition. Under the premise of the presence of CD33 positive cells, within a certain concentration range, the activation of T cells (the amount of CD69 molecules produced) is logarithmically positively correlated with the amount of EK333F. The determination of the efficient activation of T cells by EK333F under the condition of U937 is shown in Fig.10 .

[0158] Embodiment 8,

[0159] Antitumor efficacy test of bifunctional antibody CD33-CD3 (EK333F) in HL60 humanized acute promyelocytic leukemia cell mouse tumor model

[0160] 1 Test method

[0161] 1.1 Preparation of HSC-NPG humanized immune system mouse model

[0162] Four-week-old NPG female mice were irradiated with X-ray biological irradiator for 24 hours and then injected with multiple CD34+ hematopoietic stem cells from umbilical cord blood (mixed donor) through the tail vein. Blood was collected from the mice through the eye socket 20 weeks after transplantation. Blood samples were collected in EDTA-Na2 anticoagulant tubes. The content of human CD45 and CD3 positive cells in the peripheral blood of the animals was analyzed by flow cytometry to evaluate the effect of humanized immune reconstruction. HuHSC-NPG with hCD45 chimerism greater than 25% and uniform CD3+ ratio was selected for establishing a tumor-bearing model.

[0163] 1.2 Construction of HL60-luc-gfp cell line tumor model in HSC-NPG mice

[0164] HL60-luc-gfp tumor cells were cultured to the logarithmic growth phase, and the cell concentration was counted and the cell suspension concentration was adjusted to 1×107 / mL. 40 humanized HSC-NPG mice were weighed, and all animals were injected with HL-60-luc-gfp cells through the tail vein, with a volume of 0.2mL per mouse (the number of cells inoculated was 2×106). Ten days after transplantation, all animals were subjected to in vivo imaging to detect tumor-bearing conditions, and were grouped according to the total photon number by stratified randomization, with 8 females in each group, for a total of 5 groups.

[0165] 1.3 Tail vein injection of bifunctional antibody EK333F

[0166] The five groups were vehicle control group (PBS), EK333F low-dose group (1μg / mouse), EK333F medium-dose group (10μg / mouse), EK333F high-dose group (30μg / mouse) and cedabenamide control group. The vehicle and EK333F were administered by tail vein injection with a volume of 0.1 mL. The cedabenamide was administered by oral gavage with a volume of 5 mL / kg mouse body weight.

[0167] The frequency of administration of the vehicle and EK333F was twice a week for 7 consecutive weeks. The frequency of administration of the EK333F high-dose group was adjusted to once a week starting from D7. The frequency of administration of the cedabenamide control group was 3 times a week for 7 consecutive weeks.

[0168] 1.4 Animal Observation

[0169] Observe the animals at least once within 30 minutes after administration, and closely observe the reaction of the animals to the test article within 4 hours after administration. Observe once a day at non-administration time points. Observation indicators include clinical symptoms (such as animal appearance, behavior, diet, response to stimulation, secretions, excretions, etc.) and death. Record the symptoms of the animals in detail, as well as the onset time, severity, and duration of the symptoms; record the death of the animals in detail (death time, number of dead animals, dying reactions, etc.).

[0170] 1.5 In vivo imaging of tumors in small animals

[0171] After tumor loading and administration, mice were injected with luciferin substrate solution (3 mg / mouse) intraperitoneally at D7, D14, D21, D28, D35, D42, and D50. After 10 minutes, they were anesthetized by inhalation of isoflurane gas and transferred to the dark box of the living imaging instrument to image all surviving animals or dead or dying animals. The automatic exposure mode was set to take bright field and dark field pictures, and the luminescent photon intensity was automatically detected. 4.3.1》Software collects and analyzes the total number of luminescent photons

[0172] 1.6 Statistical analysis

[0173] The body weight and in vivo imaging data were obtained from The data were analyzed using Graphpad prism8.0 statistical analysis software. First, the data were tested for normal distribution and homogeneity of variance. If the data were in accordance with normal distribution (p>0.20) and homogeneity of variance (p>0.10), the LSD method of one-way analysis of variance was used for multiple comparisons among multiple groups, and p<0.05 was considered statistically significant; if the data were not in accordance with normal distribution or the variance was unequal, the Kruskal-Wallis H method of nonparametric test was used for multiple group comparisons. If the Kruskal-Wallis H test result was significant (p<0.05), the data were rank transformed and then compared between multiple groups, and p<0.05 was considered statistically significant.

[0174] The chi-square test was used for statistical analysis of animal survival, and p < 0.05 was considered statistically significant.

[0175] Normalization of the total number of photons in vivo imaging:

[0176] Relative level=(value after administration / value before administration)*100%.

[0177] Tumor inhibition rate = (1-total photon number of the drug administration group / total photon number of the control group)*100%.

[0178] 2. Results

[0179] The results of bioluminescent in vivo imaging showed that the fluorescence signal intensity of the tumors in the control group increased with the extension of time after tumor cell inoculation, indicating that the tumors in the model mice continued to grow ( Fig.10 At each imaging time point after treatment, the tumor luminescence signals of animals in the vehicle control group and the cedanilide control group were significantly stronger than those in the three different doses of EK333F treatment groups; the luminescence signal intensity of the tumor site of the animals in the treatment group (G2-G5) at different imaging time points after treatment was significantly different from that of the vehicle control group ( Fig.12 ). After 3 weeks of treatment, the higher the EK333F treatment dose, the better the tumor inhibition effect. The tumor inhibition rate was calculated by normalizing the total photon number. At D21 after treatment, the tumor inhibition rates of the EK333F medium-dose and high-dose treatment groups were both above 90%, and the dose-effect relationship was obvious. The high-dose group had the highest tumor inhibition rate (Table 3).

[0180] Table 3: Tumor inhibition rate of each treatment group

[0181]

[0182]

Claims

1. A bispecific antibody that binds to human CD33 and CD3, characterized in that: include: 1) IgG antibody that specifically binds to the cell membrane antigen CD33; 2) Single-chain antibody that binds to CD3 molecule, an antigen on the surface of T cells; The single-chain antibody that recognizes the CD3 molecule is connected to the C-terminus of the CD33 antibody light chain via a hydrophilic connecting peptide; The bispecific antibody structure is: and, Linker1: GSTSGSGKPGSGEGSTKGGS; Linker2: GGGGSGGGGSGGGGS; The VH-CH1-Hinge Region-CH2-CH3, VL-Cκ-Linker1-VH CD3 -Linker2-VL CD3 With guide peptide; Wherein, the VH-CH1-Hinge Region-CH2-CH3 amino acid sequence is encoded by SEQ ID NO: 1; The VL-Cκ-Linker1-VH CD3 -Linker2-VL CD3 The amino acid sequence is encoded by SEQ ID NO:

3.

2. Use of the bispecific antibody binding to human CD33 and CD3 as claimed in claim 1 in the preparation of a medicament for treating relapsed and refractory myeloid leukemia.

3. A pharmaceutical composition comprising the bispecific antibody according to claim 1.

4. The pharmaceutical composition according to claim 3, wherein the method of use comprises: Made into liquid preparations, made into freeze-dried preparations, and continuously administered by continuous infusion pumps.

5. The pharmaceutical composition according to claim 3, wherein the formulation comprises: Acetic acid: 0.2~0.4g / L L-methionine: 1.0~20g / L L-histidine: 1.0~2.0g / L Tween-20: 0.2~1.0g / L Sucrose: 50-150g / L.